EdgarLookup

CIENA CORP — Financial Data

Annual figures from SEC EDGAR XBRL filings (10-K)

These figures are extracted directly from XBRL-tagged financial statements that CIENA CORP filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.

Overview All Filings Annual Quarterly Insiders
2.6%
Profit Margin
Net income ÷ revenue
2.1%
Return on Assets
Net income ÷ assets
1.15x
Debt-to-Equity
Total liabilities ÷ equity
+18.8%
Revenue Growth
Year over year

Revenue

Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $4.77B Dec 12, 2025
FY2025 Nov 2, 2024 $4.01B Dec 12, 2025
FY2025 Oct 28, 2023 $4.39B Dec 12, 2025
FY2024 Oct 29, 2022 $3.63B Dec 20, 2024
FY2023 Oct 30, 2021 $3.62B Dec 15, 2023
FY2022 Oct 31, 2020 $3.53B Dec 16, 2022
FY2021 Nov 2, 2019 $3.57B Dec 17, 2021
FY2019 Oct 31, 2019 $3.57B Dec 20, 2019
FY2020 Nov 3, 2018 $3.09B Dec 18, 2020
FY2019 Oct 31, 2018 $3.09B Dec 20, 2019

Revenue (Net Sales)

Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.

Fiscal Year Period End Value Filed
FY2017 Oct 31, 2017 $2.80B Dec 22, 2017
FY2017 Oct 31, 2016 $2.60B Dec 22, 2017
FY2017 Oct 31, 2015 $2.45B Dec 22, 2017
FY2016 Oct 31, 2014 $2.29B Dec 21, 2016
FY2015 Oct 31, 2013 $2.08B Dec 21, 2015
FY2014 Oct 31, 2012 $1.83B Dec 19, 2014
FY2013 Oct 31, 2011 $1.74B Dec 20, 2013
FY2012 Oct 31, 2010 $1.24B Dec 21, 2012
FY2011 Oct 31, 2009 $652.63M Dec 22, 2011
FY2010 Oct 31, 2008 $902.45M Dec 22, 2010

Gross Profit

Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $2.00B Dec 12, 2025
FY2025 Nov 2, 2024 $1.72B Dec 12, 2025
FY2025 Oct 28, 2023 $1.88B Dec 12, 2025
FY2024 Oct 29, 2022 $1.56B Dec 20, 2024
FY2023 Oct 30, 2021 $1.72B Dec 15, 2023
FY2022 Oct 31, 2020 $1.65B Dec 16, 2022
FY2021 Nov 2, 2019 $1.54B Dec 17, 2021
FY2019 Oct 31, 2019 $1.54B Dec 20, 2019
FY2020 Nov 3, 2018 $1.31B Dec 18, 2020
FY2019 Oct 31, 2018 $1.31B Dec 20, 2019

Net Income

The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $123.34M Dec 12, 2025
FY2025 Nov 2, 2024 $83.96M Dec 12, 2025
FY2025 Oct 28, 2023 $254.83M Dec 12, 2025
FY2024 Oct 29, 2022 $152.90M Dec 20, 2024
FY2023 Oct 30, 2021 $500.20M Dec 15, 2023
FY2022 Oct 31, 2020 $361.29M Dec 16, 2022
FY2021 Nov 2, 2019 $253.43M Dec 17, 2021
FY2019 Oct 31, 2019 $253.43M Dec 20, 2019
FY2020 Nov 3, 2018 ($344.69M) Dec 18, 2020
FY2019 Oct 31, 2018 ($344.69M) Dec 20, 2019

Operating Income

Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $197.53M Dec 12, 2025
FY2025 Nov 2, 2024 $166.62M Dec 12, 2025
FY2025 Oct 28, 2023 $357.55M Dec 12, 2025
FY2024 Oct 29, 2022 $222.81M Dec 20, 2024
FY2023 Oct 30, 2021 $495.36M Dec 15, 2023
FY2022 Oct 31, 2020 $486.96M Dec 16, 2022
FY2021 Nov 2, 2019 $346.77M Dec 17, 2021
FY2019 Oct 31, 2019 $346.77M Dec 20, 2019
FY2020 Nov 3, 2018 $229.95M Dec 18, 2020
FY2019 Oct 31, 2018 $229.95M Dec 20, 2019

R&D Expense

Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $848.33M Dec 12, 2025
FY2025 Nov 2, 2024 $767.50M Dec 12, 2025
FY2025 Oct 28, 2023 $750.56M Dec 12, 2025
FY2024 Oct 29, 2022 $624.66M Dec 20, 2024
FY2023 Oct 30, 2021 $536.67M Dec 15, 2023
FY2022 Oct 31, 2020 $529.89M Dec 16, 2022
FY2021 Nov 2, 2019 $548.14M Dec 17, 2021
FY2019 Oct 31, 2019 $548.14M Dec 20, 2019
FY2020 Nov 3, 2018 $491.56M Dec 18, 2020
FY2019 Oct 31, 2018 $491.56M Dec 20, 2019

Operating Cash Flow

Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $806.09M Dec 12, 2025
FY2025 Nov 2, 2024 $514.53M Dec 12, 2025
FY2025 Oct 28, 2023 $168.33M Dec 12, 2025
FY2024 Oct 29, 2022 ($167.76M) Dec 20, 2024
FY2023 Oct 30, 2021 $541.65M Dec 15, 2023
FY2022 Oct 31, 2020 $493.65M Dec 16, 2022
FY2021 Nov 2, 2019 $413.14M Dec 17, 2021
FY2019 Oct 31, 2019 $413.14M Dec 20, 2019
FY2020 Nov 3, 2018 $229.26M Dec 18, 2020
FY2019 Oct 31, 2018 $229.26M Dec 20, 2019

Capital Expenditures (Capex)

Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $140.80M Dec 12, 2025
FY2025 Nov 2, 2024 $136.64M Dec 12, 2025
FY2025 Oct 28, 2023 $106.20M Dec 12, 2025
FY2024 Oct 29, 2022 $90.82M Dec 20, 2024
FY2023 Oct 30, 2021 $79.55M Dec 15, 2023
FY2022 Oct 31, 2020 $82.67M Dec 16, 2022
FY2021 Nov 2, 2019 $62.58M Dec 17, 2021
FY2019 Oct 31, 2019 $62.58M Dec 20, 2019
FY2020 Nov 3, 2018 $67.62M Dec 18, 2020
FY2019 Oct 31, 2018 $67.62M Dec 20, 2019

Total Assets

The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $5.86B Dec 12, 2025
FY2025 Nov 2, 2024 $5.64B Dec 12, 2025
FY2024 Oct 28, 2023 $5.60B Dec 20, 2024
FY2023 Oct 29, 2022 $5.07B Dec 15, 2023
FY2022 Oct 30, 2021 $4.87B Dec 16, 2022
FY2021 Oct 31, 2020 $4.18B Dec 17, 2021
FY2020 Nov 3, 2019 $3.95B Dec 18, 2020
FY2020 Nov 2, 2019 $3.89B Dec 18, 2020
FY2019 Oct 31, 2019 $3.89B Dec 20, 2019
FY2019 Nov 1, 2018 $3.78B Dec 20, 2019

Total Liabilities

All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $3.14B Dec 12, 2025
FY2025 Nov 2, 2024 $2.83B Dec 12, 2025
FY2024 Oct 28, 2023 $2.75B Dec 20, 2024
FY2023 Oct 29, 2022 $2.36B Dec 15, 2023
FY2022 Oct 30, 2021 $1.85B Dec 16, 2022
FY2021 Oct 31, 2020 $1.67B Dec 17, 2021
FY2020 Nov 2, 2019 $1.72B Dec 18, 2020
FY2019 Oct 31, 2019 $1.72B Dec 20, 2019
FY2019 Oct 31, 2018 $1.83B Dec 20, 2019
FY2018 Oct 31, 2017 $1.82B Dec 21, 2018

Stockholders Equity

The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $2.73B Dec 12, 2025
FY2025 Nov 2, 2024 $2.82B Dec 12, 2025
FY2025 Oct 28, 2023 $2.85B Dec 12, 2025
FY2025 Oct 29, 2022 $2.71B Dec 12, 2025
FY2024 Oct 30, 2021 $3.02B Dec 20, 2024
FY2023 Oct 31, 2020 $2.51B Dec 15, 2023
FY2022 Nov 2, 2019 $2.17B Dec 16, 2022
FY2019 Oct 31, 2019 $2.17B Dec 20, 2019
FY2021 Nov 3, 2018 $1.93B Dec 17, 2021
FY2019 Oct 31, 2018 $1.93B Dec 20, 2019

Goodwill

An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $521.20M Dec 12, 2025
FY2025 Nov 2, 2024 $444.71M Dec 12, 2025
FY2024 Oct 28, 2023 $444.77M Dec 20, 2024
FY2023 Oct 29, 2022 $328.32M Dec 15, 2023
FY2022 Oct 30, 2021 $311.65M Dec 16, 2022
FY2021 Oct 31, 2020 $310.85M Dec 17, 2021
FY2020 Nov 2, 2019 $297.94M Dec 18, 2020
FY2019 Oct 31, 2019 $297.94M Dec 20, 2019
FY2019 Oct 31, 2018 $297.97M Dec 20, 2019
FY2018 Oct 31, 2017 $267.46M Dec 21, 2018

Retained Earnings

Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 ($3.17B) Dec 12, 2025
FY2025 Nov 2, 2024 ($3.29B) Dec 12, 2025
FY2024 Oct 28, 2023 ($3.38B) Dec 20, 2024
FY2023 Oct 29, 2022 ($3.63B) Dec 15, 2023
FY2022 Oct 30, 2021 ($3.79B) Dec 16, 2022
FY2021 Oct 31, 2020 ($4.28B) Dec 17, 2021
FY2020 Nov 2, 2019 ($4.64B) Dec 18, 2020
FY2019 Oct 31, 2019 ($4.64B) Dec 20, 2019
FY2019 Nov 1, 2018 ($4.90B) Dec 20, 2019
FY2019 Oct 31, 2018 ($4.95B) Dec 20, 2019

Cash & Equivalents

Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 $1.09B Dec 12, 2025
FY2025 Nov 2, 2024 $934.86M Dec 12, 2025
FY2024 Oct 28, 2023 $1.01B Dec 20, 2024
FY2023 Oct 29, 2022 $994.35M Dec 15, 2023
FY2022 Oct 30, 2021 $1.42B Dec 16, 2022
FY2021 Oct 31, 2020 $1.09B Dec 17, 2021
FY2020 Nov 2, 2019 $904.05M Dec 18, 2020
FY2019 Oct 31, 2019 $904.05M Dec 20, 2019
FY2019 Oct 31, 2018 $745.42M Dec 20, 2019
FY2018 Oct 31, 2017 $640.51M Dec 21, 2018

Long-Term Debt

Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.

Fiscal Year Period End Value Filed
FY2022 Oct 30, 2021 $677.29M Dec 16, 2022
FY2021 Oct 31, 2020 $683.29M Dec 17, 2021
FY2017 Oct 31, 2017 $392.97M Dec 22, 2017
FY2017 Oct 31, 2016 $486.30M Dec 22, 2017

EPS (Basic)

Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 0 Dec 12, 2025
FY2025 Nov 2, 2024 0 Dec 12, 2025
FY2025 Oct 28, 2023 1 Dec 12, 2025
FY2024 Oct 29, 2022 1 Dec 20, 2024
FY2023 Oct 30, 2021 3 Dec 15, 2023
FY2022 Oct 31, 2020 2 Dec 16, 2022
FY2021 Nov 2, 2019 1 Dec 17, 2021
FY2019 Oct 31, 2019 1 Dec 20, 2019
FY2020 Nov 3, 2018 (2) Dec 18, 2020
FY2019 Oct 31, 2018 (2) Dec 20, 2019

EPS (Diluted)

Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 0 Dec 12, 2025
FY2025 Nov 2, 2024 0 Dec 12, 2025
FY2025 Oct 28, 2023 1 Dec 12, 2025
FY2024 Oct 29, 2022 1 Dec 20, 2024
FY2023 Oct 30, 2021 3 Dec 15, 2023
FY2022 Oct 31, 2020 2 Dec 16, 2022
FY2021 Nov 2, 2019 1 Dec 17, 2021
FY2019 Oct 31, 2019 1 Dec 20, 2019
FY2020 Nov 3, 2018 (2) Dec 18, 2020
FY2019 Oct 31, 2018 (2) Dec 20, 2019

Shares Outstanding

Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.

Fiscal Year Period End Value Filed
FY2025 Nov 1, 2025 141.02M Dec 12, 2025
FY2025 Nov 2, 2024 142.66M Dec 12, 2025
FY2024 Oct 28, 2023 144.83M Dec 20, 2024
FY2023 Oct 29, 2022 148.41M Dec 15, 2023
FY2022 Oct 30, 2021 154.86M Dec 16, 2022
FY2021 Oct 31, 2020 154.56M Dec 17, 2021
FY2020 Nov 2, 2019 154.40M Dec 18, 2020
FY2019 Oct 31, 2019 154.40M Dec 20, 2019
FY2019 Oct 31, 2018 154.32M Dec 20, 2019
FY2018 Oct 31, 2017 143.04M Dec 21, 2018